[ad_1]
The vaccine was claimed to have yet to complete phase 3 clinical trials in about one study published in Turkey, with a rate of 91.25 percent effective. However, on the same day, another study was published in Brazil showing that the CoronaVac vaccine was 50 to 90 percent effective.
‘Vaccination results may differ by country’
The experts stressed that the same vaccine can produce different results due to testing protocols, data sizes, and population differences, and cautioned that the published results for CoronaVac so far may cause some confusion.
The announcement of the results of the vaccine tested in 13 thousand people in Brazil was delayed 3 times at the request of Sinovac.
“Turkey’s preliminary report is not enough”
According to the report, in tests with 322 thousand volunteers in Turkey, 14 days after the administration of the second dose it was determined that 29 people were infected. In fact, authorities expected the number of patients to reach 40 to explain the test results. However, the mid-term evaluation of the evidence for the emergency use permit has been published.
In Indonesia, the situation is even more complicated
The state-affiliated Bio Farma initially announced that the vaccine’s effectiveness was 97 percent, then announced that the prevention rate could not yet be determined and that all data should be expected.
‘We need more volunteers and more infected patients’
Jerome Kim, director of the South Korea-based International Vaccine Institute, said: “If you want to reassure yourself, the data you shared first must be robust, just like Pfizer and Moderna. AstaZeneca was not as successful.
Who regarding the tests carried out in Turkey, “Only on the basis of 29 cases of coronavirus the Sinovac vaccine is difficult to determine how effective it is. The data from more volunteers to be more robust and more infected, we need a patient,” he said.
Jerome said about Kim Sinovac’s vaccine: “Based on the first information that comes with different results, it is normal not to see the same effect from Sinovac, but my last ending in January may be more interesting.”
‘China needs to disclose data transparently’
Dicky Budiman, an epidemiologist at Griffith University in Queensland, stressed that “the biggest problem in China, especially in vaccination, is transparency” due to problems that have arisen in the past.
“That is why it is very important for China to show the world the quality of its vaccines. This is something that, of course, they should explain to the world through scientific articles. used the expression.
While authorities in Sinovac have yet to make an official statement, a spokesman for China’s Foreign Ministry said that vaccine developers in the country have made progress “by adhering to scientific principles and regulatory requirements.”
Four vaccines from Sinopharm, CanSino Biologics, and the Chinese Academy of Sciences are in phase 3 stages in China.
CLICK FOR COMMENTS
[ad_2]
